Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityWyndham H. Wilson, Rod Humerickhouse, Yue Cui et al.|The Lancet Oncology|2010Cited by 852
Non-Hodgkin’s LymphomasAndrew D. Zelenetz, Furhan Yunus, Jeremy S. Abramson et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 329
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015Andrew D. Zelenetz, Hema Sundar, Leo I. Gordon et al.|Journal of the National Comprehensive Cancer Network|2015Cited by 78
Non-Hodgkin’s Lymphomas, Version 1.2013Andrew D. Zelenetz, Maoko Naganuma, William G. Wierda et al.|Journal of the National Comprehensive Cancer Network|2013Cited by 76
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Chaitra S. Ujjani, Bruce D. Cheson, Sin‐Ho Jung et al.|Blood|2016Cited by 59